NASDAQ:IMDZ Immune Design (IMDZ) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free IMDZ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.85▼$5.8550-Day Range$5.85▼$5.8552-Week Range$1.10▼$5.85VolumeN/AAverage Volume374,216 shsMarket Capitalization$282.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Design alerts: Email Address Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Immune Design Stock (NASDAQ:IMDZ)Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.Read More Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. IMDZ Stock News HeadlinesMarch 18, 2024 | msn.comMetabolic Insights into Immune Cell Activation and ResponseMarch 14, 2024 | msn.comResearchers solve mystery of how minimalist plant immune molecules become activatedMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 8, 2024 | msn.com'Double life' of key immune protein reveals new strategies for treating cancer and autoimmune diseasesMarch 8, 2024 | msn.comImmune cells can adapt to invading pathogens, deciding whether to fight now or prepare for the next battleMarch 4, 2024 | msn.comDiscovery of 'molecular machine' brings new immune therapies a step closerMarch 1, 2024 | tmcnet.comImmunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer PatientsFebruary 5, 2024 | msn.com10 Best Foods to Boost Your Immune SystemMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 31, 2024 | msn.comWhen and how immune cells form 'memories' of pathogen encounters and respond upon reinfectionJanuary 25, 2024 | msn.comNew algorithm may greatly speed up the design of 'humanized' antibodies that workJanuary 14, 2024 | msn.comJN.1 variant's spread not due to enhanced immune escape, study suggestsJanuary 11, 2024 | msn.comSmall changes in specific immune cell populations linked to autoimmune disordersJanuary 11, 2024 | msn.comNew immune system-targeting compound shows early promise in treating lupusDecember 25, 2023 | nytimes.comWhy the World Needs Its Own Immune SystemDecember 20, 2023 | msn.comImmune system plays crucial step in creating blood stem cellsDecember 18, 2023 | msn.comResearchers develop innovative and flexible method to study immune cell capabilitiesNovember 13, 2023 | markets.businessinsider.comPromising Outlook for AC Immune SA: Buy Rating Based on Potential Alzheimer Trials Success and Encouraging ABATE Study ProgressNovember 1, 2023 | msn.comSignificance of multivitamins in supporting immune healthOctober 2, 2023 | msn.comHow to keep your immune system strong this winter – according to expertsJuly 5, 2023 | msn.comTips for building your immune system naturallyJune 23, 2023 | msn.comImmune systems can be weakened by space travel - what causes such an immune deificit? - studyMay 31, 2023 | health.usnews.comHow Aging Affects Your Immune SystemMay 16, 2023 | forbes.comDigital Immune Systems: Assurance In The Midst Of VolatilityMay 2, 2023 | marketwatch.comImmune Repertoire Sequencing Market Future Outlook and Prospects till 2031April 29, 2023 | marketwatch.comImmune Repertoire Sequencing Market Market 2023-2028 Industry Research and ShareApril 4, 2023 | marketwatch.comImmune Checkpoint Inhibitors Market Size and Forecast till 2031See More Headlines Receive IMDZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Design and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2018Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:IMDZ CUSIPN/A CIK1437786 Webwww.immunedesign.com Phone206-682-0645FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,760,000.00 Net Margins-2,483.00% Pretax MarginN/A Return on Equity-49.56% Return on Assets-46.21% Debt Debt-to-Equity RatioN/A Current Ratio11.33 Quick Ratio11.32 Sales & Book Value Annual Sales$2.20 million Price / Sales128.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book3.06Miscellaneous Outstanding Shares48,370,000Free FloatN/AMarket Cap$282.96 million OptionableOptionable Beta3.48 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Carlos V. Paya (Age 60)CEO, Pres & Director Mr. Stephen R. Brady (Age 49)Exec. VP of Strategy & Fin. Dr. Jan Henrik Ter Meulen (Age 56)Chief Scientific Officer Sylvia WheelerInvestor Relations OfficerDr. Wayne R. Gombotz (Age 60)Chief Devel. Officer Key CompetitorsAkebia TherapeuticsNASDAQ:AKBAWerewolf TherapeuticsNASDAQ:HOWLFoghorn TherapeuticsNASDAQ:FHTXRAPT TherapeuticsNASDAQ:RAPTVerastemNASDAQ:VSTMView All Competitors IMDZ Stock Analysis - Frequently Asked Questions How were Immune Design's earnings last quarter? Immune Design Corp. (NASDAQ:IMDZ) posted its quarterly earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to the consensus estimate of $0.64 million. Immune Design had a negative trailing twelve-month return on equity of 49.56% and a negative net margin of 2,483.00%. What other stocks do shareholders of Immune Design own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Geron (GERN), Melinta Therapeutics (MLNT), Rigel Pharmaceuticals (RIGL), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Trevena (TRVN), TherapeuticsMD (TXMD) and Achaogen (AKAO). This page (NASDAQ:IMDZ) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Design Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.